Our motto: “patients can’t wait!”

Services

  • We focus on disruptive innovations from bench to bedside and help asset promoters and product owners to dramatically improve health outcomes in a competitive and dynamic landscape.

  • Our core focus is on in-depth qualitative and quantitative trade-off analysis, browsing all perspectives and enhancing clinical and economic value.

chevron_rightEarly engagement

POC studies should be well-designed for an efficient trade-off analysis and to inform promoters on go/no-go rules. We promote the leveraging of fast-evolving scientific knowledge to shorten the development cycle and address unmet needs in a more efficient way.


chevron_rightHealth Technology Assessment

HTA is getting more complex, detailed, and sophisticated to inform health plans and/or governments on the opportunities for funding. There is a trend towards a more in-depth clinical effectiveness and economic analysis far beyond the classical guideline endorsement or cost per QALY calculation. It is more challenging for promoters to navigate among these conflicting requests.

Sir William Osler once said to study medicine without books is to sail an uncharted sea; while to study medicine only from books is not to go to sea at all.

Medi-Qualité Omega advocates that to approach HTA without a robust academic, clinical, and economic knowledge is to sail an uncharted sea; whilst to keep your practice of HTA theoretical is not to go to sea at all. 


chevron_rightPatient access

At the end of the 20th century, we witnessed a substantial improvement in life expectancy with and without good quality of life. However, during the last two decades, the improvement in life expectancy associated with a good quality of life has almost plateaued. As a result, researchers from life sciences and IT domains, have been challenged to reduce the gap between life expectancy in good health and death. Therefore, the focus of the industry is now increasingly aimed at in-depth remission or even, complete cure. The spotlight is on the elderly, as well as on children with orphan conditions still suffering from many chronic illnesses without a cure at sight. We strongly believe that the merge between life sciences, mathematics, and computing will help to shrink long-term disabilities in the next few decades. 


chevron_rightStrategic advice

Promoters are increasingly challenged across the globe to satisfy the requirements of conflicting stakeholders and perspectives. Now more than ever, there is a need for strategic and outside-the-box thinking that goes beyond the classical geographic sequencing to re-challenge clinical and economic perspectives and values. 

Illustration - Work
Work

Our core competence

02.
Parallel/early Scientific Advice 
Official HAS/EMA/EUnetHTA
Mock Parallel/early Scientific Advice

04.
Strategic / flash assessment on EU / global submission

06.
EU Launch Sequence Strategy

01.
Investment Assessment on POC

03.
3A. Flash Advice for due diligence on a TPP

3B. Best prepare for 2025 EU Clinical effectiveness assessment

05.
HTA Advisory Board

07.
P&R Negotiation Capability-Building Workshop
US/EU/France
Emerging Markets 

Early assessment


Phase 1

01.
Investment Assessment on POC

Phase 2

02.
Parallel/early Scientific Advice 
Official HAS/EMA/EUnetHTA
Mock Parallel/early Scientific Advice

03.
3A. Flash Advice for due diligence on a TPP

3B. Best prepare for 2025 EU Clinical effectiveness assessment

Pre-Submission advice


Phase 3

04.
Strategic / flash assessment on EU / global submission

05.
HTA Advisory Board

Pre-launch


06.
EU Launch Sequence Strategy

Launch


07.
P&R Negotiation Capability-Building Workshop
US/EU/France
Emerging Markets 

Our firm collects your personal data in order to respond your request. Please fill in all the required fields. If you wish to access, delete or modify your data, please send an email to contact@mediqualite.com including "MY DATA" in the subject header.


MQO

27 rue Blomet
75015 Paris
France
+33 (0)9 66 97 82 58